Biogen's head of late-stage trials leaves for Sarepta
June 07, 2018 at 10:20 AM EDT
Gilmore O’Neill’s exit from Biogen comes at a particularly inopportune moment for the company, which is testing a potential Alzheimer’s treatment in late-stage studies.